MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 4082 8100 Fax: 00 91 (22) 4082 8181 E-mail: info@amphray.com Website: www.triochemproducts.com Corporate Identity Number: L24249MH1972PLC015544



Ref No: TPL PP 200336 2020; 27th June 2020

BSE Limited Corporate Relationship Department, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai: 400 001. Security Code No. 512101 - ISIN No.: INE331E01013.

Dear Sir / Madam,

UMBN


To

Sub: Outcome of the Board - Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulation, 2015

Pursuant to Notice of Board meeting dated 17th June, 2020 the Board meeting was held on today Saturday, 27th June, 2020 at 2.00 p.m. at 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai: 400001 and has approved the following:

- 1. The Board discussed and approved the Annual Financial Statements together with accounting policies, schedules, and explanatory notes, as reviewed by the Audit Committee, for the year ended 31st March 2020 in accordance with provision of the Companies Act, 2013.
- 2. The Board approved the Audited Financial Results for the guarter / year ended on 31st March 2020, as reviewed by the Audit Committee, in accordance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
- 3. The Board noted and took on records the Audit Report for the year ended 31st March 2020, as placed before the Board being the Unqualified Report. The approval of the Board was accorded to submit a declaration on auditors report with unmodified opinion pursuant to the SEBI Circular no. CIR/CFD/ CMD/56/2016 dated May 27, 2016 and Notification no. SEBI/LAD-NRO/2016-17/001 dated May 25, 2016.
- 4. The 48th Annual General Meeting of the Company has been fixed on Saturday, 26th September, 2020 at 3.00 P.M. at the Registered Office of the Company at Sambava Chambers, 4th Floor, Sir P. M. Road, Mumbai 400 001 and accordingly Books Closure date of the Company has been fixed from 18th September 2020 to 26th September 2020 (Both days Inclusive)

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 4082 8100 Fax: 00 91 (22) 4082 8181 E-mail: <u>info@amphray.com</u> Website: www.triochemproducts.com Corporate Identity Number: L24249MH1972PLC015544



You are requested to take note of the same.

Thanking you,

Yours faithfully,

For TRIOCHEM PRODUCTS LIMITED

RAMU S. DEORA DIRECTOR DIN: 00312369 Place: Mumbai



MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 4082 8100 Fax: 00 91 (22) 4082 8181 E-mail: info@amphray.com Website: www.triochemproducts.com Corporate Identity Number: L24249MH1972PLC015544



Ref No: TPL PP 200335 2020; 27th June 2020

To **BSE** Limited Corporate Relationship Department, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai: 400 001. Security Code No. 512101 - ISIN No.: INE331E01013.

Dear Sir / Madam,

Sub: Submission of Audited Financial Results for the Quarter and Year ended 31st March 2020

We refer to our letter dated 17th June 2020 on the captioned subject.

Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. In this subject, we wish to inform you that the Board of Director of the Company at its meeting held today i.e. Saturday, 27th June 2020 have inter-alia considered and approved the Audited Financial Results of the Company for the guarter/year ended 31st March, 2020 duly reviewed by the Audit Committee.

The said financial results, duly signed by the Director & CEO of the company along with the statutory auditor's report with unmodified opinion thereon are enclosed for your perusal and records. A declaration on auditor's report with unmodified opinion pursuant to the SEBI Circular no. CIR/CFD/CMD/ 56/2016 dated May 2, 2016 and notification no. SEBI/LAD-NRO/2016-17/001 dated May 25, 2016 is also enclosed.

Also, informed that the audited financial results in prescribed format will be published in "Free Press Journal" and "Navshakti" newspaper, as required. Please take the same in you record.

Thanking you,

Yours faithfully,

For TRIOCHEM PRODUCTS LIMITED

RAMU SITARAM DEORA

RAMU S. DEORA **DIRECTOR & CEO** DIN: 00312369 Encl.: as above



1

Digitally signed by RAMU SITARAM DEORA

Date: 2020.06.27 15:43:31 IST

Kanu Doshi Associates LLP

Chartered Accountants

Mumbai Address : 203, The Summit, Hanuman Road, Western Express Highway, Vile Parle (E), Mumbai - 400 057 T : 022-2615 0100 / 111 / 112 • F : 022 2615 0113

Pune Address : 123, Sohrab Hall, 21 Sassoon Road, Opp. Jehangir Hospital, Pune - 411001 • T : 020 4906 7177 E : info@kdg.co.in • W : www.kdg.co.in

Independent Auditor's Report on the Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulations 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Τo,

The Board of Directors of Triochem Products Limited

Opinion

We have audited the accompanying statement of Financial Results of Triochem Products Limited ("the company") for the quarter ended March 31, 2020 and the year to date statement for the period from April 01, 2019 to March 31, 2020, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these Financial results:

- (i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- (ii) give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter ended March 31, 2020 as well as the year to date statement for the period from April 01, 2019 to March 31, 2020.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Financial Results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Financial Results

These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these Financial Results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard

Kanu Doshi Associates LLP

prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Financial Results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concem basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the

Kanu Doshi Associates LLP

related disclosures in the financial statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

 Evaluate the overall presentation, structure and content of the Financial Results, including the disclosures, and whether the Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For Kanu Doshi Associates LLP Chartered Accountants Firm Registration No: 104746W/W100096

KUNAL Control and a control of the control and a control of the co

Kunal Vakharia Partner Membership No: 148916 UDIN: 20148916AAAACB3522

Place: Mumbai Date: June 27, 2020



MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 4082 8100 Fax: 00 91 (22) 4082 8181 E-mail: info@amphray.com Website: www.triochemproducts.com Corporate Identity Number: L24249MH1972PLC015544

11:10 CHEM

Ref No: TPL PP 200334 2020; 27th June 2020

BSE Limited Corporate Relationship Department, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai: 400 001. Security Code No. 512101 - ISIN No.: INE331E01013

Dear Sir / Madam,

То

Sub: Declaration on Annual Audited Financial Results pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements), Regulation 2015

The Board of Directors of the Company at its meeting held on 27th June, 2020 has approved the Audited Financial Results of the Company for the year ended 31st March, 2020 and we hereby declare that the Statutory Auditors of the Company, M/s. Kanu Doshi Associates LLP., Chartered Accountants, (FRN: 104746W/W100096) have issued an Audit Report with unmodified opinion thereon.

This declaration is issued in compliance with the provisions of the Regulation 33(3)(d) of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended by the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) (Amendment), Regulation 2016 vide notification no. SEBI/LAD-NRO/2016-17/001 dated May 25, 2016 and Circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016,

The Declaration may kindly be taken on your records.

For TRIOCHEM PRODUCTS LIMITED

RAMU SITARAM DEORA

Digitally signed by RAMU SITARAM DEORA Date: 2020.06.27 15:44:15 IST

RAMU S. DEORA **DIRECTOR & CEO** DIN: 00312369





MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001. <u>Telephone: 00 91 (22) 4082 8100 Fax: 00 91 (22) 4082 8181 E-mall: info@amphray.com</u>

Website: www.triochemproducts.com Corporate Identity Number: L24249MH1972PLC015544

	TRIOCHEM PRODUC					
	Registered Office: Sambava Chambers, 4th Floor			ai - 400 001		
	website: www.triochen		L			
	CIN: L24249MH1972		CHINED 240TH	ADOL 2020		
	AUDITED FINANCIAL RESULTS FOR THE QUARTI	SKAND YEAR	ENDED 3151 M	ARCH 2020	(Do to lab	a) Erroort EDC
	(Rs. in lakhs) Except EPS Particulars Ouarter Ended Year Ended					
Sr.	Particulars	31-03-2020	31-12-2019	31-03-2019	31-03-2020	31-03-2019
No		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
		(Refer Note	(Onaddited)	(Refer Note	(mutaneta)	(induced)
		No. 5)		No. 5)		
1	Income					
	(a) Revenue from Operations	1,147.66	541.16	339.97	2,003.18	1,235.47
	(b) Other income	33.38	12.93	1.53	46.63	5.52
	Total Income from operations	1,181.04	554.09	341.50	2,049.81	1,240.99
2	Expenses:					
-	(a) Cost of materials consumed	544.16	424.70	458.38	968.86	1,099.78
	(b) Purchase of stock-in-trade	32.77	4.78		37.55	55.60
	(c) Changes in inventory of finished goods, work-in-progress and stock-in-trade		(99.57)	(260.24)	354.67	(311.83)
	(d) Employee benefits expenses	30.41	17.04	17.61	82.33	71.90
	(e) Finance costs	5.78	9.36	8.00	22.97	45.46
	(f) Depreciation and amortisation expense	4.11	4.21	5.11	16.68	20.54
	(g) Other expenses	26.64	27.33	46.84	111.57	155.59
	Total Expenses	895.56	387.85	275.71	1,594.63	1,137.04
1						
3	Profit / (Loss) from ordinary activities before exceptional items (1-2)	285.48	166.24	65.80	455.18	103.95
4	Exceptional items	•			-	•
5	Profit / (Loss) before tax (3 +/- 4)	285.48	166.24	65.80	455.18	103.95
6	Tax expense					
	- Current tax	73.31	41.73	20.15	117.33	30.75
	- Deferred tax	(0.63)		3.32	(2.43)	(1.10)
	Total Tax expenses	72.68	43.44	23.47	114.90	29.65
7	Profit / (Loss) for the period (5 +/- 6)	212.80	122.80	42.32	340.28	74.30
8	Other comprehensive income, net of income tax					
-	A. (i) Items that will be reclassified to profit or Loss	-		-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-		-	-	
	B. (i) Items that will not be reclassified to profit or Loss	0.02	(0.03)	(0.14)	(0.30)	0.02
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.00)		0.03	0.08	(0.01)
	Total Other comprehensive income, net of income tax	0.02	(0.03)	(0.11)	(0.22)	0.01
9	Total Comprehensive income for the period (8 +/- 7)	212.82	122.77	42.21	340.06	74.31
10	Paid-up equity share capital (Face value of Rs10/- per share)	24.50	24.50	24.50	24.50	24.50
11	Reserve excluding Revalution Reserves as per balance sheet of previous accounting year				1,193.14	853.07
12	Earning per share (EPS) (of Rs.10/- each) (not annualised)					
	Basic / Diluted EPS	86.86	50.12	17.27	138.89	30.33



6

TRIOCHEM PRODUCTS LIMITED MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS



Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 4082 8100 Fax: 00 91 (22) 4082 8181 E-mall: info@amphray.com Website: www.triochemproducts.com Corporate Identity Number: 1.24249MH1972PLC015544

	STATEMENT OF AUDITED ASSETS AND LIABILITIES AS AT 31ST	MARCH, 2020	
	T		(Rs.in lakhs
Sr No	Particulars	As at 31-03-2020 Audited	As at 31-03-2019 Audited
L	ASSETS		
1	Non - Current Assets		
	(a) Property, plant and equipment	97.51	113.78
	(b) Capital work - in - progress	3.24	
	(c) Investment property	8.11	8.52
	(d) Financial assets		
	(i) Other financial assets	7.32	7.32
	(e) Other non - current tax assets	7.26	
	(f) Other non - current assets	1.19	1.15
	Sub total - Non - Current Assets	124.63	130.77
2	Current Assets		
	(a) Inventories	155.41	957.44
	(b) Financial assets		
	(i) Trade receivables	1,239.89	333.0
	(ii) Cash and cash equivalents	55.31	24.90
	(iii) Other financial assets	0.59	0.54
	(c) Other tax assets (net)	-	8.30
	(d) Other current assets	85.85	60.07
	Sub total - Current Assets	1,537.05	1,384.32
	Total - Assets	1,661.68	1,515.09
3	EQUITY AND LIABILITIES EQUITY		
	(a) Equity share capital	24.50	24.50
	(b) Other Equity	1,193.14	853.07
	Total - Equity	1,217.64	877.57
	LIABILITIES		
1	Non Current Liabilities		
	(a) Deferred tax liabilities (Net)	9.33	11.83
	Sub total - Non- Current Liabilities	9.33	11.83
2	Current liabilities		
	(a) Financial liabilities		r.
	(i) Borrowings	250.30	579.42
	(ii) Trade payables	74.01	34.13
	(b) Other financial liabilities	13.93	2.05
	(c) Other current liabilities	79.86	1.24
	(c) Provisions	9.05	8.8
	(d) Current tax liabilities (Net)	7.56	•
	Sub- total - Current Liabilities	434.71	625.69
	Total - Liabilities	444.04	637.52
	Total - Equity and Liabilities	1,661.68	1,515.0



TRIOCHEM PRODUCTS LIMITED MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS



Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001. <u>Telephone: 00 91 (22) 4082 8100 Fax: 00 91 (22) 4082 8181 E-mall: info@amphray.com</u> <u>Website: www.triochemproducts.com</u> Corporate Identity Number: L24249MH1972PLC015544

 		(Rs.in lakhs)		
Particulars		Year Ended		
	31-Mar-20	31-Mar-19		
	Audited	Audited		
CASH FLOW FROM OPERATING ACTIVITIES				
Net Profit before tax and Extraordinary Items	455.18	103.9		
Adjustment for:				
Depreciation / Amortisation	16.68	20.5		
Interest Income	(0.66)	(2.6		
Reclassification of remeasurement of employee benefits	(0.30)	0.0		
Interest Expenses	20.06	45.4		
Net gain on sale of Asset	-	(0.0		
Investment Expenses	0.05	0.0		
Sundry balance Off	(0.00)	0.3		
Operating Profit before Working Capital Changes	491.01	167.7		
Adjustments for Working Capital Changes		57		
Increase/Decrease in Assets	(33.08)	54.0		
Changes in Inventories	802.03	(134.9		
Increase/Decrease Trade Receivable	(906.88)	(333.0		
Increase/Decrease in other financial and non-financial assets	0.00	(0.0		
Increase/Decrease Trade payables	39.88	(37.6		
Increase/Decrease in other financial and non-financial liabilities	11.88	2.0		
Increase/Decrease in Liabilities	78.62	0.3		
Changes in Provision	0.20	(7.		
Cash Generated from Operations	483.66	(289.0		
Direct taxes paid / (refund)	(101.40)	(85.0		
Net Cash from Operating Activities	382.26	(374.6		
CASH FLOW FROM INVESTING ACTIVITIES				
Purchase of Fixed Assets including Capital Work in Progress	(3.24)	(0.		
Sales of Fixed Assets		0.		
Investment Expenses	(0.04)	(0.		
Interest Received	0.60	2.		
Net Cash Used in Investing Activity	(2.68)	1.		
CASH FLOW FROM FINANCING ACTIVITIES				
Net (Decrease)/ Increase in Short Term Borrowings	(329.11)	351.		
Interest Paid	(20.06)	(45.		
Net Cash Used in Financing Activity	(349.17)	305.9		
NET CHANGES IN CASH & CASH EQUIVALENTS (A+B+C)	30.41	(67.)		
OPENING BALANCE OF CASH & CASH EQUIVALENTS	24.90	91.9		
CLOSING BALANCE OF CASH & CASH EQUIVALENTS	55.31	24.9		

Notes:

The above audited financial results of the Company for the quarter and year ended March 31,2020 have been reviewed by the Audit committee of the Board and approved by the Board of Directors at its meeting held on 27.06.2020



MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 4082 8100 Fax: 00 91 (22) 4082 8181 E-mall: info@ amphray.com



Website: www.triochemproducts.com Corporate Identity Number: 1.24249MH1972PLC015544

2)	The Audited financial results have been prepared in accordance with Indian Accounting Standards (Ins AS), the provisions of the Companies Act, 2013 (the
	Act), as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI).
3)	The Company has adopted Ind AS 116, effect annual reporting period beginning April 1, 2019. The effect on adoption of Ind AS 116 on the financial results
	is insignificant.
4)	The Company operates in single segment only, i.e. chemical and pharmaceuticals, the disclosure requirement of Indian Accounting Standard (IND AS-108)
	"Segment Reporting" is not applicable.
5)	The figure for quarter ended 31st March, 2020 and 31st March 2019 are the balancing figures between audited figures of the full financial year and the
	reviewed year-to-date figures up to the third quarter of the relevant financial year.
6)	The company has assessed the possible effects that may result from the COVID-19 pandemic on the carrying amounts of receivables and other assets /
	liabilities. Based on the current indicators of economic conditions, the company expects to recover the carrying amount of all its assets. The actual impact
	of the COVID-19 pandemic may be different from that estimated as at the date of approval of these financial results and the company will continue to closely
	monitor any material changes to the economic conditions in the future.
7)	The Corresponding figures of the previous quarter / year have been regrouped, recasted and reclassified to make them comparable wherever necessary.
	FOR TRIOCHEM PRODUCTS LIMITED
	The PRODUCE
	RAMU SITARAM DEORA Digitally signed by RAMU SITARAM DEORA
	RAMU SITARAM DEORA
	Date: 2020.06.27 15:44:49 IST RAMU S. DEORA
	Place: Mumbai DIRECTOR & CEO
	Dated: 27th June, 2020 DIN: 00312369

9

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Sr

No

1

2

3

4


5

6

8

Notes:

Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 4082 8100 Fax: 00 91 (22) 4082 8181 E-mall: info@amphray.com Website: www.triochemproducts.com Corporate Identity Number: L24249MH1972PLC015544



provisions of the Companies Act, 2013 (the Act), as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI).

3) The Company has adopted Ind AS 116, effect annual reporting period beginning April 1, 2019. The effect on adoption of Ind AS 116 on the financial results is insignificant.

4) The Company operates in single segment only, i.e. chemical and pharmaceuticals, the disclosure requirement of Indian Accounting Standard (IND AS-108) "Segment Reporting" is not applicable.

5) The figure for quarter ended 31st March, 2020 and 31st March 2019 are the balancing figures between audited figures of the full financial year and the reviewed year-to-date figures up to the third quarter of the relevant financial year.




10

niel(o

CHEM

MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, <u>PIN: 400001. Telephone: 00 91 (22) 4082 8100 Fax: 00 91 (22) 4082 8181</u> <u>E-mall: info@amphray.com Website: www.triochemproducts.com</u> <u>Corporate Identity Number: L24249MH1972PLC015544</u>



11

CHEM